06896.HK
Golden Throat Holdings Group Company Limited
HKSE · Healthcare · Drug Manufacturers - Specialty & Generic · CN
HKD 1.95
+2.90%Year over year
Reported trailing growth
- Revenue
- -7.7%
- EBITDA
- -19.6%
- EBIT
- -14.2%
- EPS
- -21.0%
- Free cash flow
- -8.2%
- Operating cash flow
- -19.7%
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- —
- EPS
- —
Three-year CAGR
- Revenue
- -1.7%
- EBITDA
- -7.1%
- EBIT
- -5.3%
- Net income
- -3.7%
- EPS
- -3.6%
- Free cash flow
- -32.7%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026